<DOC>
	<DOCNO>NCT01653639</DOCNO>
	<brief_summary>This single dose , open-label , randomize , crossover study subject severe Hemophilia A compare bioavailability 2 different strength Kogenate FS ( BAY 14-2222 ) .</brief_summary>
	<brief_title>Comparative Pharmacokinetic Study Two Different Strengths BAY14-2222</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Males , age 18 65 year Subjects Severe hemophilia A documented plasma FVIII level &lt; 1 % &gt; /= 150 ED ( exposure day ) FVIII concentrate ( ) support medical record Evidence current past inhibitor antibody History congenital acquire coagulation disorder hemophilia A Platelet count &lt; 75,000/mm3 Abnormal renal function ( serum creatinine &gt; 2 time upper limit normal range ) Active liver disease verify medical history persistently elevate alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 5x upper limit normal severe liver disease evidence , limit following : International Normalized Ratio ( INR ) &gt; 1.4 , hypoalbuminemia , portal vein hypertension include presence otherwise unexplained splenomegaly history esophageal varix</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>BAY14-2222</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>